Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Larimar Therapeutics, Inc.

NASDAQ: LRMR · Life Sciences · 10 alerts · CIK 1374690

Share price
$3.00Close, Nov 16
Market cap
$314M
Shares outstanding
104.63MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Larimar Therapeutics, Inc. filings on SEC EDGAR ↗

8:33 AM ET 10-Q
Financial Results

Larimar Therapeutics Q3 2026 Results: Net Loss of $31.1M, Loss Narrows

Larimar Therapeutics reported a net loss of $31.1 million for the third quarter of 2026, an improvement from the $47.7 million loss in the prior year period, primarily driven by a significant decrease in research and development expenses. The company strengthened its balance sheet through equity issuances, ending September 30, 2026, with $128.7 million in cash, cash equivalents, and marketable securities.

Key figure
Net loss $31.1M
7:18 AM ET 8-K
Financial Results

Larimar Therapeutics Financial Results

Larimar Therapeutics reported third quarter 2026 financial results and announced the completion of its rolling BLA submission to the FDA for nomlabofusp in Friedreich’s ataxia. The company ended the quarter with $128.7 million in cash, providing a projected runway into late Q2 2027 as it prepares for a potential U.S. launch in Q3 2027.

“Completing the BLA submission for nomlabofusp marks a major milestone for Larimar and the Friedreich’s ataxia (FA) community. The next 12 months are expected to bring several pivotal registrational catalysts, including FDA review of our application and progression of FORWARD-FA, our global confirmatory Phase 3 study.”

Carole Ben-Maimon, M.D., Chief Executive Officer

“In parallel, we are preparing for a potential U.S. launch in the third quarter of 2027, if approved, while evaluating options to support global commercialization.”

Carole Ben-Maimon, M.D., Chief Executive Officer
9:32 PM ET Form 4
Insider Buying

Larimar Therapeutics Director Thomas Edward Hamilton Buys $187K of Stock

Thomas Edward Hamilton, Director, bought 70,000 shares of Larimar Therapeutics, Inc. at $2.67 a share, worth $187K in total on Nov 12, 2026. Shares held after the trade: 70,000.

Value
$187K
Shares
70,000
Price
$2.67
Role
Director
Trade date
Nov 12, 2026
6:03 PM ET Form 4
Insider Buying

Larimar Therapeutics President and CEO Carole Ben-maimon Buys $50K of Stock

Carole Ben-maimon, President and CEO, bought 18,050 shares of Larimar Therapeutics, Inc. at $2.77 a share, worth $50K in total on Nov 11, 2026. Shares held after the trade: 386,326 (+4.9%).

Value
$50K
Shares
18,050
Price
$2.77
Role
President and CEO
Holding change
+4.9%
Trade date
Nov 11, 2026
6:01 PM ET Form 4
Insider Buying

Larimar Therapeutics Director Frank E. Thomas Buys $21.8K of Stock

Frank E. Thomas, Director, bought 8,000 shares of Larimar Therapeutics, Inc. at $2.73 a share, worth $21.8K in total on Nov 11, 2026. Shares held after the trade: 15,000 (+114.3%).

Value
$21.8K
Shares
8,000
Price
$2.73
Role
Director
Holding change
+114.3%
Trade date
Nov 11, 2026
6:00 PM ET Form 4
Insider Buying

Larimar Therapeutics President and COO John B. Harlow Jr. Buys $49.9K of Stock

John B. Harlow Jr., President and COO, bought 17,800 shares of Larimar Therapeutics, Inc. at $2.80 a share, worth $49.9K in total on Nov 11, 2026. Shares held after the trade: 67,800 (+35.6%).

Value
$49.9K
Shares
17,800
Price
$2.80
Role
President and COO
Holding change
+35.6%
Trade date
Nov 11, 2026
5:57 PM ET Form 4
Insider Buying

Larimar Therapeutics CFO Michael Celano Buys $50K of Stock

Michael Celano, CFO, bought 18,460 shares of Larimar Therapeutics, Inc. at $2.71 a share, worth $50K in total on Nov 11, 2026. Shares held after the trade: 234,245 (+8.6%).

Value
$50K
Shares
18,460
Price
$2.71
Role
CFO
Holding change
+8.6%
Trade date
Nov 11, 2026
5:55 PM ET Form 4
Insider Buying

Larimar Therapeutics Chief Development Officer Gopi Shankar Buys $13.5K of Stock

Gopi Shankar, Chief Development Officer, bought 5,000 shares of Larimar Therapeutics, Inc. at $2.71 a share, worth $13.5K in total on Nov 11, 2026. Shares held after the trade: 81,443 (+6.5%).

Value
$13.5K
Shares
5,000
Price
$2.71
Role
Chief Development Officer
Holding change
+6.5%
Trade date
Nov 11, 2026
4:10 PM ET 8-K
Business Update

Larimar Therapeutics Business Update

Larimar Therapeutics has completed its rolling Biologics License Application (BLA) submission to the FDA seeking accelerated approval for nomlabofusp in Friedreich’s ataxia. The filing also includes a preliminary cash balance of $128.7 million as of September 30, 2026, and an updated corporate presentation for investor meetings.

Counterparty
FDA

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.